News
BMRN
112.20
-0.57%
-0.64
Sangamo: Still Not Convincing Enough
Seeking Alpha · 21h ago
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Merck & Company (MRK)
TipRanks · 1d ago
SVB Leerink Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $130
Benzinga · 1d ago
--SVB Securities Adjusts BioMarin Pharmaceutical's Price Target to $130 From $122, Maintains Outperform Rating
--SVB Securities Adjusts BioMarin Pharmaceutical's Price Target to $130 From $122, Maintains Outperform Rating
MT Newswires · 1d ago
BioMarin: Tactical Allocation Playing Roctavian Approval
Seeking Alpha · 3d ago
BioMarin: Priced For Perfection
Seeking Alpha · 3d ago
BioMarin: Opportunity To Score Home Run With Latest Regulatory Advancements
Seeking Alpha · 4d ago
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
Benzinga · 4d ago
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Benzinga · 5d ago
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Benzinga · 5d ago
BMO Capital Initiates Coverage On Biomarin Pharmaceutical with Market Perform Rating, Announces Price Target of $107
Benzinga · 5d ago
BioMarin Pharmaceutical (BMRN) Gets a Hold from BMO Capital
TipRanks · 5d ago
BMO Capital Initiates BioMarin Pharmaceutical at Market Perform With $107 Price Target
BMO Capital Initiates BioMarin Pharmaceutical at Market Perform With $107 Price Target
MT Newswires · 5d ago
Ascendis: Neutral On Skytrofa's Market Launch, Initiating With A Neutral Rating
Seeking Alpha · 01/27 17:33
Morgan Stanley Remains a Buy on BioMarin Pharmaceutical (BMRN)
TipRanks · 01/24 16:25
Healthcare Outlook 2023
Seeking Alpha · 01/23 15:02
Global drug spending to reach $1.9T by 2027 – IQVIA
Seeking Alpha · 01/22 17:00
ClearBridge Sustainability Leaders Strategy Q4 2022 Portfolio Manager Commentary
Seeking Alpha · 01/20 07:20
GNOM: Healthcare Dashboard For January
Seeking Alpha · 01/19 14:00
Insider Sell: Biomarin Pharmaceutical
Insider Sell: Biomarin Pharmaceutical
MT Newswires · 01/19 01:38
More
Webull provides a variety of real-time BMRN stock news. You can receive the latest news about Biomarin Pharmaceutical Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRN
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.